Hyundai Bioscience has launched the Phase II clinical trial of a new broad-spectrum antiviral agent, CP-COV03, for the treatment of Covid-19 patients.
The antiviral drug, developed in Korea as a universal treatment for diseases including Covid-19, has the ‘viral removal’ mechanism that is applicable to all viral infections.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Existing antiviral agents act on only specific viruses.
CP-COV03 is administered orally and comprises active ingredient niclosamide. It has a pharmacological action that promotes ‘autophagy’ mechanism to help human cells eliminate viruses.
In this process, cells identify the virus as a foreign substance and remove it themselves.
Hyundai Bioscience said in a statement: “If CP-COV03 is confirmed to be effective against Covid-19 in this clinical study, it means that a universal antiviral drug is born not only for Covid-19 and its variants, but also for almost all other viruses such as influenza, hepatitis, AIDS, Ebola, and herpes.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCP-COV03, which is currently evaluated in Phase II clinical trial, is similar to the human efficacy test of penicillin conducted in 1941, in several ways.
Hyundai Bioscience further added: “The discovery of a substance with the mechanism that kills bacteria led to the 20th century medicine called penicillin and that CP-COV03 with a mechanism to eliminate viruses by promoting autophagy will be the first universal antiviral drug like penicillin.”
As a broad-spectrum antiviral agent, CP-COV03 is expected to enable a quick preemptive treatment for viral infection, thereby preventing pandemics.
In December last year, Hyundai Bioscience reported that a combination of CP-COV03 with anti-inflammatory therapy, dexamethasone, showed to be effective in people with severe Covid-19, in a study.
